Skip to main content
Premium Trial:

Request an Annual Quote

David Bellitt, Paul James, Erik Wallden, and Gary Costley


Serologicals said last week that David Bellitt has been appointed president of the company’s new Celliance division (see News Scan, this issue).

Bellitt joined Serologicals in December 2002 as vice president of global commercial operations, and he will continue as a corporate vice president of the company, Serologicals said.

Paul James has resigned as senior vice president of commercial operations of Biacore International, the company said last week. His resignation was unexpected and “due to personal family reasons,” the company said in a statement. Biacore is currently searching for a successor and plans to fill James’ post by early 2005. In the meantime, company CEO Erik Wallden will be responsible for all of Biacore’s commercial operations.

Gary Costley has been elected to the board of directors of NanoBio, the Ann Arbor, Mich.-based company said last week. Costley also serves on the board of directors of Accelrys, among other companies.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.